Literature DB >> 503106

Myoadenylate deaminase deficiency.

J B Shumate, R Katnik, M Ruiz, K Kaiser, C Frieden, M H Brooke, J E Carroll.   

Abstract

Myoadenylate deaminase (adenosine monophosphate deaminase--AMPDA) was recently shown to be deficient in a group of patients by use of a histochemical and biochemical method based on the elaboration of ammonia by this enzyme as it deaminates 5' AMP. We have confirmed the utility of this histochemical method and the existence of persons deficient in AMPDA through the use of an unrelated assay technique. The lack of enzyme activity is not associated with any inhibitory activity in the muscles of patients with this disorder. The clinical diversity of these patients suggests that this lack may represent a normal variant or a subclinical state rather than an actual disease. The occurrence of AMPDA deficiency in both sexes points to possible autosomal inheritance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 503106     DOI: 10.1002/mus.880020309

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  19 in total

1.  Type 2a fibre rhabdomyolysis in myoadenylate deaminase deficiency.

Authors:  C Zimmer; H Altenkirch; S Dorfmüller-Küchlin; D Pongratz; I Paetzke; G Gosztonyi
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

2.  Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans.

Authors:  M A Tarnopolsky; G Parise; M J Gibala; T E Graham; J W Rush
Journal:  J Physiol       Date:  2001-06-15       Impact factor: 5.182

3.  Histochemical demonstration of differences in AMP deaminase activity in rat skeletal muscle-fibres.

Authors:  R A Meyer; J Gilloteaux; R L Terjung
Journal:  Experientia       Date:  1980-06-15

Review 4.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi
Journal:  Klin Wochenschr       Date:  1987-11-02

5.  Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.

Authors:  H Morisaki; T Morisaki; L K Newby; E W Holmes
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.

Authors:  R L Sabina; J L Swain; C W Olanow; W G Bradley; W N Fishbein; S DiMauro; E W Holmes
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

7.  Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency.

Authors:  R L Sabina; J L Swain; B M Patten; T Ashizawa; W E O'Brien; E W Holmes
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

8.  Myoadenylate deaminase deficiency in a patient with facial and limb girdle myopathy.

Authors:  R Mercelis; J J Martin; I Dehaene; T de Barsy; G Van den Berghe
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

9.  Myoadenylate deaminase deficiency: absence of correlation with exercise intolerance in 452 muscle biopsies.

Authors:  R Mercelis; J J Martin; T de Barsy; G Van den Berghe
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

10.  Myoadenylate deaminase deficiency with severe rhabdomyolysis.

Authors:  F A Baumeister; M Gross; D R Wagner; D Pongratz; R Eife
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.